Form DEFA14A JANUS ASPEN SERIES

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

(Amendment No. )

 

 

Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

Check the appropriate box:

 

☐	Preliminary Proxy Statement

 

☐	Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

 

☐	Definitive Proxy Statement

 

☐	Definitive Additional Materials

 

☒	Soliciting Material Pursuant to § 240.14a-12

Janus Aspen Series

(Exact Name of Registrant as Specified in Charter)

151 Detroit Street, Denver, Colorado 80206-4805

(Address of Principal Executive Offices)

303-333-3863

(Registrant’s Telephone No., including Area Code)

Abigail Murray — 151 Detroit Street, Denver, Colorado 80206-4805

(Name and Address of Agent for Service)

Payment of Filing Fee (Check the appropriate box):

 

☒		No fee required.
☐		Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0—11.
		(1)		Title of each class of securities to which transaction applies:
		(2)		Aggregate number of securities to which transaction applies:
		(3)		Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
		(4)		Proposed maximum aggregate value of transaction:
		(5)		Total fee paid:
☐		Fee paid previously with preliminary materials:
☐		Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
		(1)		Amount Previously Paid:
		(2)		Form, Schedule or Registration Statement No.:
		(3)		Filing Party:
		(4)		Date Filed:

 

 

 

---

Janus Henderson Global Technology and Innovation Portfolio and

Janus Henderson Research Portfolio,

each a series of Janus Aspen Series

YOUR IMMEDIATE ATTENTION IS REQUESTED

Dear Shareholder:

We have been trying to reach you for the last several weeks regarding important proposals relating to your investments in the Janus Aspen Series. We cannot hold the meeting without attaining quorum and therefore need your immediate participation. The Special Meeting will reconvene on January 21, 2025.

This letter was sent to you because you held shares on the record date and we have not received your vote.

Please vote today using one of the following options:

 

1.

VOTE ONLINE

Log on to the website or scan the QR code shown on your proxy card. Please have your proxy card in hand and follow the on-screen instructions.

 

2.

VOTE BY TOUCH-TONE TELEPHONE

Call the automated tollfree number listed on your proxy card. Please have your proxy card in hand and follow the recorded instructions.

 

3.

VOTE WITH A LIVE AGENT

If you would like to vote with a live agent you can call (866) 467-3858 and provide your control number and the agent will process your vote over the phone. You will receive a confirmation in the mail of your vote within 5 days.

 

4.

VOTE BY MAIL

Complete, sign and date the proxy card and then return it in the enclosed postage paid envelope.

A copy of the Proxy Statement may be viewed or downloaded at the website listed on your enclosed proxy card. If you have any questions regarding the proposals, or need assistance with voting, please call Computershare Fund Services, the Fund’s proxy solicitor, toll free at 1-866-467-3858.

YOUR FUND BOARD RECOMMENDS THAT YOU VOTE “FOR” THE PROPOSAL(S)

Thank you for your prompt attention to this matter.

 

JH ADJ 2024

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Coolbrook Secures Business Finland Funding to Accelerate Electrification for the Global Steel Industry
• Jean Baptiste de Boissieu Joins Strategic Value Partners as Managing Director on European Investment Team
• AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata